Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)
Close on Nov 18, 2026Market cap $1.75BP/E –Yield –
Ultragenyx Pharmaceutical r&d expenses
Research and development expenses are spending on new products and technology.
Ultragenyx Pharmaceutical's R&D Expenses for the twelve months ending Jun 30, 2026 was $773.49M, up 12.3% year over year. For fiscal 2025 it was $750.00M, up 7.4% from the year before. Over ten years it grew 20.7% a year on average. The highest annual figure on record is $750.00M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $750.00M | +7.4% |
| FY2024 | Dec 31, 2024 | $698.00M | +7.7% |
| FY2023 | Dec 31, 2023 | $648.00M | -8.2% |
| FY2022 | Dec 31, 2022 | $705.79M | +42.0% |
| FY2021 | Dec 31, 2021 | $497.15M | +20.6% |
| FY2020 | Dec 31, 2020 | $412.08M | +15.3% |
| FY2019 | Dec 31, 2019 | $357.36M | +21.6% |
| FY2018 | Dec 31, 2018 | $294.00M | +26.9% |
| FY2017 | Dec 31, 2017 | $231.64M | +26.4% |
| FY2016 | Dec 31, 2016 | $183.20M | +59.7% |
| FY2015 | Dec 31, 2015 | $114.74M | +149.6% |
| FY2014 | Dec 31, 2014 | $45.97M | +65.2% |
| FY2013 | Dec 31, 2013 | $27.83M | +120.1% |
| FY2012 | Dec 31, 2012 | $12.64M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $167.00M | +1.2% |
| Q1 FY2026 | Mar 31, 2026 | $187.00M | +12.7% |
| Q4 FY2025 | Dec 31, 2025 | $203.28M | +8.2% |
| Q3 FY2025 | Sep 30, 2025 | $216.21M | +27.1% |
| Q2 FY2025 | Jun 30, 2025 | $165.00M | +2.2% |
| Q1 FY2025 | Mar 31, 2025 | $166.00M | -7.0% |
| Q4 FY2024 | Dec 31, 2024 | $187.90M | +17.4% |
| Q3 FY2024 | Sep 30, 2024 | $170.11M | +8.2% |
| Q2 FY2024 | Jun 30, 2024 | $161.50M | -2.1% |
| Q1 FY2024 | Mar 31, 2024 | $178.49M | +7.7% |
| Q4 FY2023 | Dec 31, 2023 | $160.11M | -6.3% |
| Q3 FY2023 | Sep 30, 2023 | $157.25M | -33.7% |
| Q2 FY2023 | Jun 30, 2023 | $164.95M | +6.7% |
| Q1 FY2023 | Mar 31, 2023 | $165.70M | +15.7% |
| Q4 FY2022 | Dec 31, 2022 | $170.81M | +38.9% |
| Q3 FY2022 | Sep 30, 2022 | $237.30M | +109.2% |
| Q2 FY2022 | Jun 30, 2022 | $154.53M | +36.5% |
| Q1 FY2022 | Mar 31, 2022 | $143.16M | -3.0% |
| Q4 FY2021 | Dec 31, 2021 | $123.01M | -6.2% |
| Q3 FY2021 | Sep 30, 2021 | $113.42M | +29.9% |
| Q2 FY2021 | Jun 30, 2021 | $113.21M | +40.3% |
| Q1 FY2021 | Mar 31, 2021 | $147.52M | +30.6% |
| Q4 FY2020 | Dec 31, 2020 | $131.10M | +57.8% |
| Q3 FY2020 | Sep 30, 2020 | $87.31M | -12.8% |
| Q2 FY2020 | Jun 30, 2020 | $80.71M | -16.0% |
| Q1 FY2020 | Mar 31, 2020 | $112.96M | +44.6% |
| Q4 FY2019 | Dec 31, 2019 | $83.06M | +16.0% |
| Q3 FY2019 | Sep 30, 2019 | $100.14M | +43.0% |
| Q2 FY2019 | Jun 30, 2019 | $96.05M | +25.0% |
| Q1 FY2019 | Mar 31, 2019 | $78.11M | +3.4% |
| Q4 FY2018 | Dec 31, 2018 | $71.62M | +16.4% |
| Q3 FY2018 | Sep 30, 2018 | $70.04M | +15.9% |
| Q2 FY2018 | Jun 30, 2018 | $76.84M | +31.5% |
| Q1 FY2018 | Mar 31, 2018 | $75.50M | +47.3% |
| Q4 FY2017 | Dec 31, 2017 | $61.53M | +21.2% |
| Q3 FY2017 | Sep 30, 2017 | $60.41M | +24.0% |
| Q2 FY2017 | Jun 30, 2017 | $58.44M | – |
| Q1 FY2017 | Mar 31, 2017 | $51.27M | – |
| Q4 FY2016 | Dec 31, 2016 | $50.75M | – |
| Q3 FY2016 | Sep 30, 2016 | $48.71M | – |
See a number that looks wrong?